People · Operator
Named in public records as an officer, director or promoter · active 2016–2024 · Biotechnology, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| eGenesis, Inc. | — | Biotechnology | Series D+ | $265.0M | $316.4M | 2016 |
| Talaris Therapeutics, Inc. | — | Biotechnology | Series D+ | $115.0M | $4.4B | 2020 |
| Satellos Bioscience Inc. | — | Biotechnology | Series B | $64.1M | $145.6M | 2023 |
| Replicel Life Sciences Inc. | — | Other Technology | Pre-Seed | $5.5M | $867K | 2017 |
| Gemstone BioTherapeutics, LLC | — | Biotechnology | Seed | $2.3M | $31.1M | 2016 |
Geoff MacKay at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Geoff MacKay on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Steven Gillis | 1 | 23 |
| Elizabeth Williams | 1 | 9 |
| DAVID HALL | 1 | 8 |
| PAUL SEKHRI | 1 | 7 |
| Brad Smith | 1 | 6 |
| Bob More | 1 | 6 |
| Lucio Iannone | 1 | 6 |
| Mark McDade | 1 | 5 |
| Scott Requadt | 1 | 5 |
| MICHAEL LIGGETT | 1 | 5 |
| Julie Sunderland | 1 | 5 |
| David Oros | 1 | 5 |
| Isaac Ciechanover | 1 | 5 |
| George Davis | 1 | 4 |
| Peter Lewis | 1 | 4 |
| Francois Nader | 1 | 3 |
| PETER JENSEN | 1 | 3 |
| Sapna Srivastava | 1 | 3 |
| Adam Mostafa | 1 | 3 |
| Boris Nikolic | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.